Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva plus Avastin in advanced liver cancer
NCT00605722Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Primary endpoint: Percentage of Participants With Progression-free Survival at 16 weeks. Started Mar 2008; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00605722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605722.